// App-Quantinova.ai

TPS473 : APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).

Researchers

Presenter

  • Margaret A. Tempero

Principal Investigators

  • Dana Backlund Cardin

  • David Goldstein

  • Eileen Mary O'Reilly

  • Philip Agop Philip

  • Hanno Riess

  • Teresa Macarulla

  • Lotus Yung

  • Mingyu Li

  • Brian D. Lu

  • Andrew Biankin

Medical Centers

  • University of California, San Francisco, San Francisco, CA

  • Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN

  • Prince of Wales Hospital, University of New South Wales, Cancer Survivors Centre, Sydney, Australia

  • David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY

  • Karmanos Cancer Institute, Detroit, MI

  • Internistischen Onkologie/Campus Virchow-Klinikum, Charite-Universitaetsmedizin, Berlin, Germany

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Celgene Corporation, Summit, NJ

  • Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom

Locations

  • United States

  • Australia

  • Germany

  • Spain

  • United Kingdom

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Infectious Diseases (ID)

Disease

  • Pancreatic cancer

  • Hepatitis B

  • Solid malignancies

Biomarkers

  • Carbohydrate antigen 19-9

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Superiority

Phase

  • III

Study Id's

  • NCT01964430

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved